Skip to main content

Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF".

Publication ,  Journal Article
Fordyce, CB; Piccini, JP; Patel, MR
Published in: Circulation
November 29, 2016

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

November 29, 2016

Volume

134

Issue

22

Start / End Page

e532 / e533

Location

United States

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Stroke
  • Rivaroxaban
  • Humans
  • Factor Xa Inhibitors
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anticoagulants
  • 4207 Sports science and exercise
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fordyce, C. B., Piccini, J. P., & Patel, M. R. (2016). Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF". Circulation, 134(22), e532–e533. https://doi.org/10.1161/CIRCULATIONAHA.116.025258
Fordyce, Christopher B., Jonathan P. Piccini, and Manesh R. Patel. “Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF".Circulation 134, no. 22 (November 29, 2016): e532–33. https://doi.org/10.1161/CIRCULATIONAHA.116.025258.
Fordyce, Christopher B., et al. “Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF".Circulation, vol. 134, no. 22, Nov. 2016, pp. e532–33. Pubmed, doi:10.1161/CIRCULATIONAHA.116.025258.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

November 29, 2016

Volume

134

Issue

22

Start / End Page

e532 / e533

Location

United States

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Stroke
  • Rivaroxaban
  • Humans
  • Factor Xa Inhibitors
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anticoagulants
  • 4207 Sports science and exercise